{"url_path":"/sec/labt/8-k/2026-06-17/item-5-03","section_key":"item-5-03","section_title":"Item 5.03 Amendments to Articles of Incorporation","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/2079272/0001213900-26-069512-index.html","accession_number":"0001213900-26-069512","cik":"0002079272","ticker":"LABT","issuer_name":"Lakewood-Amedex Biotherapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2079272/0001213900-26-069512-index.html","primary_entity_key":"0002079272","primary_entity_name":"Lakewood-Amedex Biotherapeutics Inc."},"word_count":384,"has_tables":true,"body_markdown":"** **\n\n**Item 5.03 Amendments to Articles of Incorporation\nor Bylaws; Change in Fiscal Year.**\n\n** **\n\nOn June 15, 2026, Lakewood-Amedex Biotherapeutics\nInc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of\nthe State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued\nand outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split\nwill become effective at 4:01 p.m., Eastern Time, on June 19, 2026, and the Company’s Common Stock will begin trading on a split-adjusted\nbasis when the Nasdaq Stock Market (“Nasdaq”) opens on June 22, 2026. The Reverse Stock Split was unanimously approved by\nthe Company’s Board of Directors on June 1, 2026.\n\n \n\nAs a result of the Reverse Stock Split, every\nten (10) shares of the Company’s issued and outstanding Common Stock will be exchanged for one (1) share of Company’s Common\nStock with any fractional shares being rounded up to the next higher whole share. Once effective, the Reverse Stock Split will reduce\nthe current number of issued and outstanding shares of Common Stock from approximately 17,506,577 million to approximately 1,750,789 million.\nEquitable adjustments will be made to the number of shares of the Company’s Common Stock issuable upon exercise or conversion of\nthe Company’s equity awards, preferred stock and warrants and the number of shares issuable under the Company’s equity incentive\nplans, as well as the applicable conversion prices and exercise prices for such equity awards, preferred stock and warrants, in accordance\nwith their terms. In addition, concurrent with the Reverse Stock Split, a proportionate reduction will be made to the Company’s\nauthorized shares of Common Stock such that the Company shall have 12,500,000 shares of authorized Common Stock after the effective time\nof the Reverse Stock Split.\n\n \n\nThe Company’s Common Stock will continue\nto trade on The Nasdaq Capital Market under the existing symbol “LABT”, but the security has been assigned a new CUSIP number\n(51255A201).\n\n \n\nThe foregoing description of the Certificate of\nChange does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Change which\nis filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference."}